Prognostic markers in patients who underwent transplantation and in those who did not
. | SCT N = 98 . | . | No SCT17 N = 242 . | . | ||
|---|---|---|---|---|---|---|
| Characteristic and cut-off . | % . | Median survival, mos. . | % . | Median survival, mos. . | ||
| cTnT | ||||||
| Less than 0.035 μg/L | 86 | NR | 56 | 17 | ||
| Greater than or equal to 0.035 μg/L | 14 | 26.1 | 44 | 3.7 | ||
| cTnI* | ||||||
| Less than 0.10 μg/L | 57 | NR | 46 | 16.4 | ||
| Greater than or equal to 0.10 μg/L | 43 | 66.1 | 54 | 5.9 | ||
| NT-proBNP† | ||||||
| Less than 332 ng/L | 52 | NR | 40 | 20.0 | ||
| Greater than or equal to 332 ng/L | 48 | 66.1 | 60 | 5.8 | ||
| Ejection fraction | ||||||
| Less than 50% | 92 | NR | 68 | 14.0 | ||
| Greater than or equal to 50% | 8 | NR | 32 | 3.9 | ||
| Septal thickness | ||||||
| Less than or equal to 15 mm | 76 | NR | 67 | 12.3 | ||
| Greater than 15 mm | 24 | NR | 33 | 4.3 | ||
| cTnT Idealized Risk Score‡ | ||||||
| 1 | 11 | NR | 11 | 23.4 | ||
| 2 | 82 | NR | 52 | 16.4 | ||
| 3-5 | 7 | 26.1 | 38 | 2.9 | ||
| cTnI Idealized Risk Score*‡ | ||||||
| 1 | 23 | NR | 11 | 17.0 | ||
| 2 | 72 | NR | 52 | 11.1 | ||
| 3 | 5 | 66.1 | 32 | 2.2 | ||
| cTnT/NT-proBNP stage†§ | ||||||
| I-t | 49 | NR | 33 | 26.4 | ||
| II-t | 38 | NR | 30 | 10.5 | ||
| III-t | 13 | 8.4 | 37 | 3.5 | ||
| cTnI/NT-proBNP stage†§ | ||||||
| I-i | 35 | NR | 24 | 27.2 | ||
| II-i | 38 | NR | 38 | 11.1 | ||
| III-i | 27 | 21.6 | 38 | 4.1 | ||
. | SCT N = 98 . | . | No SCT17 N = 242 . | . | ||
|---|---|---|---|---|---|---|
| Characteristic and cut-off . | % . | Median survival, mos. . | % . | Median survival, mos. . | ||
| cTnT | ||||||
| Less than 0.035 μg/L | 86 | NR | 56 | 17 | ||
| Greater than or equal to 0.035 μg/L | 14 | 26.1 | 44 | 3.7 | ||
| cTnI* | ||||||
| Less than 0.10 μg/L | 57 | NR | 46 | 16.4 | ||
| Greater than or equal to 0.10 μg/L | 43 | 66.1 | 54 | 5.9 | ||
| NT-proBNP† | ||||||
| Less than 332 ng/L | 52 | NR | 40 | 20.0 | ||
| Greater than or equal to 332 ng/L | 48 | 66.1 | 60 | 5.8 | ||
| Ejection fraction | ||||||
| Less than 50% | 92 | NR | 68 | 14.0 | ||
| Greater than or equal to 50% | 8 | NR | 32 | 3.9 | ||
| Septal thickness | ||||||
| Less than or equal to 15 mm | 76 | NR | 67 | 12.3 | ||
| Greater than 15 mm | 24 | NR | 33 | 4.3 | ||
| cTnT Idealized Risk Score‡ | ||||||
| 1 | 11 | NR | 11 | 23.4 | ||
| 2 | 82 | NR | 52 | 16.4 | ||
| 3-5 | 7 | 26.1 | 38 | 2.9 | ||
| cTnI Idealized Risk Score*‡ | ||||||
| 1 | 23 | NR | 11 | 17.0 | ||
| 2 | 72 | NR | 52 | 11.1 | ||
| 3 | 5 | 66.1 | 32 | 2.2 | ||
| cTnT/NT-proBNP stage†§ | ||||||
| I-t | 49 | NR | 33 | 26.4 | ||
| II-t | 38 | NR | 30 | 10.5 | ||
| III-t | 13 | 8.4 | 37 | 3.5 | ||
| cTnI/NT-proBNP stage†§ | ||||||
| I-i | 35 | NR | 24 | 27.2 | ||
| II-i | 38 | NR | 38 | 11.1 | ||
| III-i | 27 | 21.6 | 38 | 4.1 | ||